Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 2, 2012, Pages

  Goloudina, Anastasia R ^a   Tanoue, Kan ^b   Hammann, Arlette ^a   Fourmaux, Eric ^a   Le Guezennec, Xavier ^c   Bulavin, Dmitry V ^c   Mazur, Sharlyn J ^b   Appella, Ettore ^b   Garrido, Carmen ^a,d   Demidov, Oleg N ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^d DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Bcl 2 family; Caspases; Dephosphorylation; Intestine

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 1; CISPLATIN; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PROTEIN WIP1; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG SENSITIZATION; ENZYME ACTIVITY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL LINE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DNA PRIMERS; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MICE; NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASES; PLASMIDS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84856004863     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1107017108     Document Type: Article

References (57)

1. Harris SL, Levine AJ (2005) The p53 pathway: Positive and negative feedback loops. Oncogene 24:2899-2908. (Pubitemid 40638098)
2. Martin AC, et al. (2002) Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat 19:149-164. (Pubitemid 34121806)
3. Momand J, Jung D, Wilczynski S, Niland J (1998) The MDM2 gene amplification database. Nucleic Acids Res 26:3453-3459. (Pubitemid 28347214)
4. Bond GL, HuW, Levine AJ (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5:3-8. (Pubitemid 40321795)
5. Lu X, et al. (2007) The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 12:342-354. (Pubitemid 47539308)
6. Meek DW, Anderson CW (2009) Posttranslational modification pf p53: cooperative integrators of function. Cold Spring Harbor Perspect Biol 1:a000950.
7. Bulavin DV, et al. (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31:210-215.
8. Hirasawa A, et al. (2003) Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 9:1995-2004. (Pubitemid 36687618)
9. Fujimoto H, et al. (2006) Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ 13:1170-1180. (Pubitemid 43905597)
10. Oliva-Trastoy M, et al. (2007) The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase. Oncogene 26:1449-1458. (Pubitemid 46340814)
11. Shreeram S, et al. (2006) Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell 23:757-764. (Pubitemid 44308587)
12. Lu X, Nannenga B, Donehower LA (2005) PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 19:1162-1174. (Pubitemid 40696183)
13. Shreeram S, et al. (2006) Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J Exp Med 203:2793-2799. (Pubitemid 46026157)
14. Demidov ON, et al. (2007) The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 26:2502-2506. (Pubitemid 46597262)
15. Demidov ON, et al. (2007) Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine. Cell Stem Cell 1:180-190. (Pubitemid 47215589)
16. Bulavin DV, et al. (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 36:343-350. (Pubitemid 38437256)
17. Kong W, Jiang X, Mercer WE (2009) Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax. Cancer Biol Ther 8(6).
18. Bouchet BP, de Fromentel CC, Puisieux A, Galmarini CM (2006) p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol 58:190-207. (Pubitemid 43796080)
19. el-Deiry WS (1998) Regulation of p53 downstream genes. Semin Cancer Biol 8:345-357.
20. Aas T, et al. (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814. (Pubitemid 26225099)
21. Wattel E, et al. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148-3157.
22. Demidova AR, Aau MY, Zhuang L, Yu Q (2009) Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control. J Biol Chem 284:4132-4139.
23. Greenow KR, Clarke AR, Jones RH (2009) Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene 28:1443-1453.
24. Bang J, Yamaguchi H, Durell SR, Appella E, Appella DH (2008) A small molecular scaffold for selective inhibition of Wip1 phosphatase. ChemMedChem 3:230-232.
25. Takekawa M, et al. (2000) p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 19:6517-6526.
26. Lin DL, Chang C (1996) p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily. J Biol Chem 271:14649-14652.
27. Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ (1987) Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84:7716-7719. (Pubitemid 18035728)
28. Zaidi SK, et al. (2007) Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci USA 104:19861-19866.
29. Onodera Y, et al. (2010) Runx2 in human breast carcinoma: Its potential roles in cancer progression. Cancer Sci 101:2670-2675.
30. Eliseev RA, et al. (2008) Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis. Oncogene 27:3605-3614. (Pubitemid 351793799)
31. Wee HJ, Huang G, Shigesada K, Ito Y (2002) Serine phosphorylation of RUNX2 with novel potential functions as negative regulatory mechanisms. EMBO Rep 3:967-974. (Pubitemid 35256471)
32. Shen R, et al. (2006) Cyclin D1-cdk4 induce runx2 ubiquitination and degradation. J Biol Chem 281:16347-16353.
33. Wong ES, et al. (2009) p38MAPK controls expression of multiple cell cycle inhibitors and islet proliferation with advancing age. Dev Cell 17:142-149.
34. Wang Z, Sun Y (2010) Targeting p53 for novel anticancer therapy. Transl Oncol 3:1-12.
35. Tan DS, et al. (2009) PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 15:2269-2280.
36. Rayter S, et al. (2008) A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene 27:1036-1044. (Pubitemid 351253192)
37. Belova GI, Demidov ON, Fornace AJ, Jr., Bulavin DV (2005) Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis. Cancer Biol Ther 4:1154-1158. (Pubitemid 41598573)
38. Lu X, et al. (2008) The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 27:123-135.
39. Natrajan R, et al. (2009) Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 15:2711-2722.
40. Brautigan DL, et al. (2005) Allosteric activation of protein phosphatase 2C by D-chiro-inositol- galactosamine, a putative mediator mimetic of insulin action. Biochemistry 44:11067-11073. (Pubitemid 41209042)
41. Bae SC, Lee YH (2006) Phosphorylation, acetylation and ubiquitination: The molecular basis of RUNX regulation. Gene 366:58-66.
42. Jonason JH, Xiao G, Zhang M, Xing L, Chen D (2009) Post-translational regulation of Runx2 in bone and cartilage. J Dent Res 88:693-703.
43. Ge C, et al. (2009) Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor. J Biol Chem 284:32533-32543.
44. Kugimiya F, et al. (2007) GSK-3beta controls osteogenesis through regulating Runx2 activity. PLoS ONE 2:e837.
45. Park OJ, Kim HJ, Woo KM, Baek JH, Ryoo HM (2010) FGF2-activated ERK mitogen-activated protein kinase enhances Runx2 acetylation and stabilization. J Biol Chem 285:3568-3574.
46. Ito Y (2004) Oncogenic potential of the RUNX gene family: 'Overview'. Oncogene 23:4198-4208.
47. Edlich F, et al. (2011) Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell 145:104-116.
48. Zhang XW, Xu B (2000) Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin- induced apoptosis in Hep G2 cells. Anticancer Drugs 11:747-756.
49. Semaan SJ, Nickells RW (2010) The apoptotic response in HCT116BAX-/- cancer cells becomes rapidly saturated with increasing expression of a GFP-BAX fusion protein. BMC Cancer 10:554.
50. Komarov PG, et al. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285:1733-1737. (Pubitemid 29428873)
51. Christophorou MA, et al. (2005) Temporal dissection of p53 function in vitro and in vivo. Nat Genet 37:718-726. (Pubitemid 41754888)
52. Choi J, et al. (2002) Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol 22:1094-1105. (Pubitemid 34094846)
53. Komarova EA, et al. (2004) Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 23:3265-3271. (Pubitemid 38669816)
54. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI (2006) The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443:214-217. (Pubitemid 44387609)
55. Junttila MR, Evan GI (2009) p53-a Jack of all trades but master of none. Nat Rev Cancer 9:821-829.
56. Grignani F, et al. (1998) High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res 58:14-19. (Pubitemid 28027708)
57. Yamaguchi H, et al. (2005) Substrate specificity of the human protein phosphatase 2Cdelta, Wip1. Biochemistry 44:5285-5294. (Pubitemid 40489968)